title: Biological disease modifying anti-rheumatic drugs.
authors.affiliation: Byrdine F Lewis School of Nursing, College of Health and Human Sciences, Georgia State University, Atlanta, GA, USA.
authors.forename: Lisa A
authors.initials: LA
authors.lastname: Cranwell-Bruce
mesh_terms: D000069594:Abatacept; D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000191:economics / Q000503:physiopathology; D003365:Costs and Cost Analysis; D000068800:Etanercept; D006801:Humans; D018796:Immunoconjugates / Q000494:pharmacology / Q000627:therapeutic use*; D007074:Immunoglobulin G / Q000494:pharmacology / Q000627:therapeutic use; D000069285:Infliximab; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D018796:Immunoconjugates; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000069594:Abatacept; C529000:golimumab; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept